Carme (@carmecrouss) header
Carme (@carmecrouss) profile picture

R5 Oncologia Mèdica Hospital Clínic de Barcelona

Joined November 2013
Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)Photo by Carme (@carmecrouss)
Very happy to share our review on Hippo-YAP/TEAD pathway which I had the opportunity to contribute during my rotation at @UTMDAnderson I’m grateful for those months of learning & the opportunity to take part in projects like this. Thanks @DrMirallas, Dr Yap & all the co-authors
🚀 Our review on Hippo–YAP/TEAD pathway is now out in Pharmacology & Therapeutics @Sciencedirect @Scopus We discuss the: 🧬 Biology 💊 Emerging drugs 🎯 Early clinical proof-of-concept ❌ Resistance mechanisms ☣️ Toxicities and where the field may go next Thanks Dr. Yap for the support and mentorship @UTMDAnderson and to the rest of co-authors for their great work Dr. Tan, Crous, Selvadurai and Lynch👏🏽 #YAP #TEAD #HippoPathway #CancerResearch #DrugDevelopment @OncoAlert @myESMO @_SEOM @ASCO 👇🏽👇🏽 Full article: sciencedirect.com/science/ar…
2
62
Proud to be at #ESMO2026 in Madrid with the Clínic Barcelona team 💙💚 Over 30 scientific contributions across tumour types, reflecting the work of so many colleagues. Thank you to everyone involved for your dedication to research and patient care. @hospitalclinic @idibaps
5
47
1,610
Que emocionant, el meu primer professor de la primera classe a la Facultat!
Quan algú fa les coses molt bé, amb molt esforç i constància, amb vocació d'ensenyar i aprendre, amb humilitat i discreció i, a més, ho fa de manera excel·lent, passa això. El Prof Dr @ToniTrilla s'ha jubilat com a Degà de Medicina de la @UniBarcelona la primera de l'Estat
1
5
266
☝🏼Eo! Estás en SEOM? Pues aquí os dejo 2 pósters espectaculares en #SEOM26 de las Dras. Carlota Rubio y @carmecrouss 👏🏼 @hospitalclinic Dra. Rubio - 🧬 Un atlas unicelular del microambiente tumoral en cáncer de mama, identificando un gradiente inmunológico y un subgrupo HER2+ especialmente “caliente” Dra. Crous -🛡️ Una revisión sistemática y metaanálisis del perfil de toxicidad inmunomediada órgano-específica y mortalidad en tumores genitourinarios 2 trabajos de muchísimo nivel y 2 paradas obligatorias en el congreso 🚨 Speechless 😶 ¡felicidades a ambas! @_SEOM @OncoAlert
6
14
1,130
💥Póster destacado #SEOM26 📍irAEs órgano-específica y mortalidad asociada a ICI en tumores GU ⚠️ irAEs: 45.3% ady vs. 28.6% M1 ▶️ Alter endocrinas ++ en ady > M1 ▶️ Nefritis ++ en M1 > ady ☠️ 21 muertes por ICI, siendo la 🫁 la causa + frecuente
1
6
315
🎉 Cisplatin or Carboplatin? That is the question ✔️ Only high-certainty evidence signal was found for Cis>Carbo in ORR urothelial, and the no PFS difference Cis=Carbo in ovarian. ❌ Most of the guidelines-based recommendations are low or ultra low GRADE based evidence 🫂 An honour to work with great colleagues and keep learning Prof Harrington @MattGalsky Prof Colombo @EnriquetaFelip Dr Rodon @juditsanz Dr Pereira @PaulJiL @OncoAlert @brunolarvol @OncBrothers @myESMO @ASCO @_SEOM @UTMDAnderson Full manuscript 👇🏽👇🏽 jamanetwork.com/journals/jam…
The eternal question in solid tumor oncology, almost Shakespearean in its persistence When is Cisplatin better than Carbo? When are they equivalent? Excited to share our new paper in @JAMANetworkOpen where we examined the certainty of evidence of the 11 major meta-analyses (12 683 pts) on which guidelines based their recommendations ✴️Several efficacy variables have low or very low level of certainty ✳️Only high-certainty evidence signal was found for Cis>Carbo in ORR urothelial, and the no PFS difference Cis=Carbo in ovarian. 🟡Despite high heterogeneity impacting GRADE across tumour types, toxicities show known correlations The story does not end here, highlighting the utility of meta-data appraisals and current evidence gaps. We might not need new trials, just greater access to data from completed studies #oncology @myESMO @ASCO 👏An honour to have worked with and learned from this faculty Prof Harrington @MattGalsky Prof Colombo @EnriquetaFelip Dr Rodon @juditsanz Dr Pereira @DrMirallas @OncoAlert @brunolarvol @OncBrothers
8
25
3,672
Contenta d’haver pogut participar al 5è congrés de la Societat Catalana d’Oncologia parlant sobre les novetats en la neoadjuvància del TVMI Ben acompanyada per l’equip d’oncologia de l’@hospitalclinic @SCBdOncologia
1
77
💥Poster session #ASCO26 📍Clinical impact & molecular profiling of PTENloss & TMPRSS2:ERG in mHSPC ➕correlation between PTENloss & TE+ ❌ PTENloss/TE- had the worst clinical outcomes ✅ Among PTENloss, TE+ presented better outcomes>TE- 🧬 PTENloss/TE+ had enrichment of PI3K – at Chicago, IL
1
4
1
9
2,408
#ASCO26 🚀 After office @ASCO Day 2 Networking with colleagues from @VHIO @hospitalclinic @UTMDAnderson @carmecrouss @OncoAlert – at Chicago, IL
4
15
899
Day#2 of #AACR26! Carpe Diem! With my well dressed phase 1 fellows! @MDAndersonnews
2
1
1
33
1,724
Si t’interessa l’oncologia mèdica, no dubtis en venir a les portes obertes de l’@hospitalclinic el dia 20 de març!! T’estarem esperant 😊 Pots contactar-nos si tens qualsevol dubte👇🏻
Te interesa la Oncología Médica? Ven el día 20 de marzo a las puertas abiertas del ⁦@hospitalclinic⁩ a conocer nuestro servicio o contáctanos para cualquier duda! #MIR #MIR2025 ⁦⁩ #residentsCLÍNIC #CLÍNIC #medicina #residentes #oncología #oncologíamédica
7
444
Has fet el #MIR2024# i estàs interessat en Oncologia Mèdica?😄 Vine a la nostra Jornada de Portes Obertes! T’esperem! @hospitalclinic @prat_aleix @MuozMateu @badamo20 @LauraMezquitaMD
3
11
1
21
5,216
🚩Mensajes clave de Javier Marco. Un PS ≥2, la enfermedad oncológica metastásica o la imposibilidad de realizar tratamiento oncoespecífico tras el ingreso en UCI se asocian con una > mortalidad al año en los supervivientes a la UCI. 👉 El médico internista que realiza asistencia compartida en unidades de oncología juega un papel central y debe aportar la visión holística y ejercer de enlace entre l@s especialistas en oncología y l@s de cuidados intensivos. 👉Pacientes en curso de tratamientos neo/adyuvantes o con enfermedades oncológicas EIV candidatos a tratamientos de beneficio potencialmente excepcional con PS 0-1 y buena calidad de vida se benefician de ingresar en UCI. @javi_mrco #44SEMI
2
3
4
1,504
I am glad to share our latest publication where we highlight the use of targeted nanoparticles as a clear new therapeutic strategy for solid tumors. This approach reduces side effects while enhancing the efficacy of tyrosine kinase inhibitors. mdpi.com/2218-273X/13/11/164…
5
19
1,398
Great presentation by @Teresa_Gorria at #EANO2023 of our study on TERTp C228T mutation as a prognostic factor in patients with Glioblastoma IDH-wt 🧠🧬 @EPineda_ONCO @BalanaCarme Check out our results 👇👀 – at Rotterdam, The Netherlands
2
4
17
1,142
🧬C228T mut was the most frequent TERTp mut in our cohort (55%) ❌C228T mut is an independent prognostic factor of worse survival ✅C250T mut improves prognosis ⏩️We propose to consider TERT mut status as a new prognostic factor – at Rotterdam, The Netherlands
2
6
543
Heading to Rotterdam #EANO2023📍Grateful to present the results of our study on TERTp C228T mutation as a prognostic factor in patients with Glioblastoma IDH-wild type 🧠🧬 @carmecrouss @EPineda_ONCO @BalanaCarme & co 🕝 Friday, September 22nd, 18h. Poster Pitch Session
1
4
20
1,277
Un año más juntos en el congreso #SEOM23 🙌🏽📍 #resisOncClinic participando en: -Caso Clínico Molecular: Sd. Cowden y cáncer de mama🧬-Dr.Javi Muñoz -Comunicación GU: Horario de infusión IO y Ca.Renal⏱️ @lauragnzaguado @laiafernandezm -Póster destacado en SNC🧠@carmecrouss &🙋🏽‍♀️
2
5
29
1,522
MEDICINA AMB PERSPECTIVA DE GÈNERE #COMBinem 👩‍⚕️Ponents: Dra. Blanca Collvinent i Dra. Mireia Puig 🗓️ 27 de Juny ⏰ 18:00 📍 Sala Panoràmica COMB i online. Ens parlaran de la importància d'aplicar la perspectiva de gènere per oferir una mirada més àmplia i una atenció de qualitat
1
3
6
881